{"ticker": {"uuid": "ebb04529-48ea-42a2-8d97-68a5f565504a", "symbol": "ICCC", "name": "ImmuCell Corporation", "exchange": "NASDAQ", "country": "US", "sector": "Healthcare", "industry": "Biotechnology"}, "articles": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Price to earnings forward of ImmuCell Corporation \u2013 NASDAQ:ICCC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVG0xOUdsSVEzNjhMeUZQb0RMWkdZZjR0NFVEVHVxUHhtSlR3S05oVVhWUGhwVnpVTkhWT3Z2eGY0d1YwOVVsTEt5Z3NkeE5DbjhVeElQanJzbHRrUFltaGNSTWo2Nnhjb3dOc25paEt6V1VscmVVRlN6dFJGcTdLUnFybE5uOU9PRHRzcmlpS0J6a3MtSDFxTlBIVERDQ3JWd2c?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T17:52:14+00:00", "published_display": "15 Jul 2026 17:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Immucell Corporation (ICCC) Affects Rotational Strategy Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUHNpdTV6ei0wQUpXdWpGY1czOU4wTm5oY0JfMXZJM0N3LVlZLXI1X2NJcThEQmM1TVhmZ1g3MUxYRHVtamJEdjVXdE54UDlNM09GSEE0UkhLdkkyVTJtd0tpR3BSSXo1S0FjNURfN2hsbWhNWVlDWUoxVUlpOG1Mci0xRzVLSGs4TDUwbzc0WjVUT0NybmdJeV9fX0xib3g3UkNIaXgyWi02Q2JfSW5KRTBLY0F6Sms0b2R6Zlc4Q3RISXNBSmMtT05zWkZtRDB1Wlp5NVR2UDA4QzQ?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T20:54:01+00:00", "published_display": "13 Jul 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results", "summary": "ImmuCell Corporation has reported strong preliminary, unaudited sales results for the second quarter and first six months of 2026. The company saw a 11.5% increase in total product sales to $7.2 million in Q2 2026 compared to Q2 2025, primarily driven by a significant 27.7% rise ", "url": "https://www.manilatimes.net/2026/07/10/tmt-newswire/globenewswire/immucell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a-21-increase-in-the-first-six-months-of-2026-based-on-preliminary-unaudited-sales-results/2382009", "source_name": "The Manila Times", "published_at": "2026-07-10T17:09:08", "published_display": "10 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPRzFQYWtVYUdvakNHRldvVTdIUzhEazVIbE5FakdkdFhHRVJ4eVBuY2piLW9hTVVtbHhsQlhDcUN4X0lPajFWSi1EMUxMSjZwNHRMMXRSZXJtNEF5czVDbHgzLWVpTm53T0hFMElCVVU1S21vUnM4MDhwZ1h1UmNuX3djOEZJSEkxQ2FVTmZPTXRWbWluMmFTTmtvOFVDaS1VdHowTDU0ZUtqUkVNQlEyZjhR?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T13:45:00+00:00", "published_display": "10 Jul 2026 13:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Insider Confidence Rewarded, Stock Hits US$96m Market Cap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T10:08:08+00:00", "published_display": "10 Jul 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products", "summary": "ImmuCell (Nasdaq: ICCC) announced preliminary, unaudited Q2 2026 product sales of $7.2 million, an 11.5% increase year over year, with domestic sales rising 27.7%. For the first half of 2026, total product sales reached $17.5 million, up 20.9% compared to 2025. Strong U.S. demand", "url": "https://www.stocktitan.net/news/ICCC/immu-cell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a2w43qb9wckg.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:09:30", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell reports Q2 product sales up 11.5% to $7.2M; six\u2011month sales up 20.9% to $17.5M", "summary": "ImmuCell (ICCC) announced preliminary, unaudited product sales for Q2 2026 reached $7.2 million, an 11.5% increase year-over-year, with six-month sales up 20.9% to $17.5 million. The growth was primarily driven by a 27.7% increase in domestic sales, attributed to improved product", "url": "https://www.tradingview.com/news/tradingview:f04eebfa35c19:0-immucell-reports-q2-product-sales-up-11-5-to-7-2m-six-month-sales-up-20-9-to-17-5m/", "source_name": "TradingView", "published_at": "2026-07-09T20:09:30", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9%", "summary": "ImmuCell Corporation reported preliminary Q2 2026 sales of $7.2 million, an 11.5% increase year-over-year, driven by strong domestic demand, though international sales declined significantly. For the first six months of 2026, total product sales rose 20.9% to $17.5 million. The c", "url": "https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-18ef7c8f2c86.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:09:30", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70 - Inverse ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUUJpSUtKbExwYldkc1ktaVY2VmxZU3ZoYUotVDg5MlpMZEN1TU11dC1qMjFpVnl3Uzk3aDFMOWZqTjVYZE83MDYyWFQtZ3ZsOF9MNVZIVjJaT0tPaWNsSFlwakl1aHBhbm5KZUxvY0lFeWxBTmg3cXEwTldERVdtM01tTndaZE5jdEVkdUh0bGNhUkNtM1k4ZDRHc3Z2b0NEVXh5akh3eHd3MDBTZUg2RkMtSDhlVjJGWExBZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T13:40:14+00:00", "published_display": "01 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70 - Volume Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNZ2lLNXZKNG5zcmNlcGRtUjdNRl9XbWkyT3pIdHVmVE9ObnF3dHczSlFESUlTbHRMdE8wdm5VbjNxeXoxOHpISGk1VEh4Njd4RE1Dc0lKNWlKRmM0Wjk5UXU0RWg2cDM3Y0d2WTgxQWdnQjFMdkdVOUpSclBJM2xYMWUwTGtrYy1zSGJJdlQ1ckVsMWRuQmswMlJUVENPS1dpR25qTGJ4WDhVNG5GUExtSGx3R2NoX1JaMlI1VWV3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T13:33:34+00:00", "published_display": "01 Jul 2026 13:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell adds Jacee Lancaster to Commercial Team", "summary": "ImmuCell Corp. announced the hiring of Jacee Lancaster as sales and marketing manager for its Western region, marking the company's fifth new hire in three months. Lancaster will focus on supporting dairy and beef producers, veterinarians, and distribution partners in understandi", "url": "https://www.feedstuffs.com/agribusiness-news/immucell-adds-jacee-lancaster-to-commercial-team", "source_name": "Feedstuffs", "published_at": "2026-07-01T14:10:14", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell", "summary": "This Zacks Analyst Blog highlights research reports for five companies: JPMorgan Chase & Co. (JPM), Novartis AG (NVS), Qualcomm Inc. (QCOM), Genie Energy Ltd. (GNE), and ImmuCell Corp. (ICCC). The report provides insights into each company's recent performance, growth drivers, an", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-jpmorgan-092600802.html", "source_name": "Market source", "published_at": "2026-06-26T05:26:00", "published_display": "26 Jun 2026 05:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell CEO buys $75,960 in common stock", "summary": "ImmuCell Corp's CEO, Paul Francis Olivier te Boekhorst, recently acquired 8,000 shares of common stock for $75,960. This purchase follows a significant 60.85% jump in the company's shares over the past six months and a strong first quarter in 2026, marking the first time ImmuCell", "url": "https://www.investing.com/news/insider-trading-news/immucell-ceo-buys-75960-in-common-stock-93CH-4752698", "source_name": "Investing.com", "published_at": "2026-06-22T13:10:48", "published_display": "22 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ImmuCell Corporation For: 22 June By Investing.com", "summary": "This article reports on a Form 4 filing for ImmuCell Corporation on June 22. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be filed by company insiders when they trade shares of their own company's stock. The article ", "url": "https://ng.investing.com/news/stock-market-news/form-4-immucell-corporation-for-22-june-93CH-2567738", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T13:10:48", "published_display": "22 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy", "summary": "ImmuCell CEO Paul Francis Olivier te Boekhorst has increased his direct holdings in the company by purchasing 8,000 shares of common stock at $9.495 per share. This open-market transaction, filed on June 18, 2026, brings his total direct ownership to 17,785 shares. The purchase s", "url": "https://www.stocktitan.net/sec-filings/ICCC/form-4-immucell-corp-de-insider-trading-activity-8199032d5fe4.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:10:48", "published_display": "22 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ICCC's Valuation Remains Premium: Is it Worth Overpaying for?", "summary": "ImmuCell Corporation (ICCC) shares are trading at a premium valuation compared to the industry average, but the article argues that this is justified due to the company's strong operational progress, market-share gains, and long-term growth prospects. Key factors include improved", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ICCC/pressreleases/2540286/icccs-valuation-remains-premium-is-it-worth-overpaying-for/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T09:09:56", "published_display": "19 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of ImmuCell Corp's (ICCC) shareholder structure, listing major individual and institutional holders. It also presents a historical view of institutional shareholding over several quarters and details recent shareholder activity, includin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T06:09:44", "published_display": "19 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for ImmuCell Corp (ICCC), highlighting its business segments and regional contributions. The data, updated on April 6, 2026, shows that the First Defense\u00ae product line accounts for the vast majority of revenue at 99.29%, with the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T05:44:27", "published_display": "19 Jun 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ImmuCell Corp's (ICCC) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page also displays current stock information for ICCC,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:44", "published_display": "19 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immucell Shareholders Approve Governance Measures at 2026 Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxONkFXNml5YjBaUHNJR2hjc2cwc3FFZkcyWjFBZFJIYTFBRnREZjZySkJpZmlBOHh2VFMxR0FncnlNZjMweVlOWFd3ZHVyY1Axd3hqcW4xNElxRGhwWnlNaHBzNmNMV0hsa19iMGUwTlZjSjlwdmVKUmtOMkRyNWljZUduSU1FeUhTZUp1anBhRVBDYkVEX3pBdmlUZjVZQklQNnhuRDhKT2lNTElpdEpKeFpzdVlzS09zT1F0bkUxNWNYVkJBOC1jVXk3NzY2RDZiRXVZbHV3eGhsV0lmbS1kVWZRVHU?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for ImmuCell Corp (ICCC), noting its current valuation score of 8.62, which ranks it 76th out of 157 in the Pharmaceuticals industry. The P/E ratio is reported at -153.81, showing a significant deviation from recent highs and lows. Key v", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:44:27", "published_display": "18 Jun 2026 07:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell shareholders approve director elections and key proposals at annual meeting", "summary": "ImmuCell Corporation (NASDAQ:ICCC) shareholders approved the election of seven directors and several key proposals at their 2026 Annual Meeting. Over 81% of eligible shares were represented, and proposals included executive compensation, the 2025 Stock Option and Incentive Plan, ", "url": "https://www.investing.com/news/sec-filings/immucell-shareholders-approve-director-elections-and-key-proposals-at-annual-meeting-93CH-4748058", "source_name": "Investing.com", "published_at": "2026-06-17T19:11:12", "published_display": "17 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (NASDAQ: ICCC) investors approve directors, pay plan, auditor", "summary": "ImmuCell Corporation's stockholders approved all proposals at their 2026 annual meeting, including the election of seven directors", "url": "https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-89a572dcd1e5.html", "source_name": "Stock Titan", "published_at": "2026-06-17T18:19:13", "published_display": "17 Jun 2026 18:19", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for ImmuCell Corp (ICCC), noting its current score of 2.85, ranking 113 out of 157 in the Pharmaceuticals industry. It highlights the company's beta of 0.54, indicating its stock tends to underperform in up-markets but experiences smaller d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-16T19:10:13", "published_display": "16 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ImmuCell Corp (ICCC), covering its price momentum score, support and resistance levels, and various technical indicators and moving averages. The current price momentum score for ICCC is 6.44, and the stock is trading between a resist", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/technical", "source_name": "TradingKey", "published_at": "2026-06-16T19:10:13", "published_display": "16 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for ImmuCell Corp (ICCC), stating that no earnings forecast score is currently available for the company. It notes that the Pharmaceuticals industry average score is 7.84. The article also mentions that relevant data for financial forecas", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T12:40:25", "published_display": "16 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Institutional Confidence", "summary": "ImmuCell Corp (ICCC) has an institutional shareholding score of 3.00, placing it 94th in the Pharmaceuticals industry. Institutional investors hold 23.86% of the company's shares, an increase of 17.57% quarter-over-quarter. James Simons is the largest institutional shareholder, h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T07:11:12", "published_display": "16 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) Q1 2026 Earnings: Positive EPS Surprise Amid Revenue Gap and Stock Dip - Earnings Beat Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcHVUMm51dC1UNURjMFNBOWVCbk5PZVBXTTFXZzlxTlRXc1FVdHZZRFdoVFdrZ05vWjdQY1QxcU9paTZBb0ladkdFb2RXR1hRYjdaYUpGYmJJbEdHempCT2kzYndVd2ZFcXJOVGRXVUlhcE1nUExpT0RXUTNvQTVtQVMwa1pLdFVoOHVyYjVMcFVQQTA1RW53M3htcU1xZEp2a2R3Y0FPYmlWczlIV0VISDhSOWdzR2Q3c09PYzFlWDhIRmp5Mnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iccell plans $3.5M First Defense capacity boost | ICCC 8-K Filing", "summary": "ImmuCell Corporation (NASDAQ: ICCC) has announced a significant manufacturing capacity expansion for its flagship First Defense\u00ae product line, shifting resources from its previously planned Re-Tain\u00ae production. The first phase, costing approximately $3.5 million and taking about ", "url": "https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-22781eac1776.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:39:00", "published_display": "10 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (ICCC) Edges Higher as Stock Tests Resistance Near $10.19 - Bull Pennant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOU215VXh2ek9SRld1Y21KWUM0REEwWVBsWTN4VGo2cXVybmF1eDQ5ZjBZRHNuVVZwMnNBbUIxQjN5S1Q2NC15VUU1SkRWaEVBejBaZlVGUGJnQXItS0VNZG1RbU5vbnR5cFZ0WmVvU1g5dDIzeDU3WnRyTVQ4YlVjWGVKWGluQ2FyZER6dExtdXMwTjhYT2tWTVFRTkdLODY2MkxMeE14aG9yRjNGUTh6YzJrY3kxU05x?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand", "summary": "ImmuCell (ICCC) reported strong first-quarter 2026 results with product sales up 28.4% to $10.4 million and net income rising 34% to $1.9 million. The company's performance was driven by robust demand for its First Defense calf-scours prevention products, particularly Tri-Shield,", "url": "https://finance.yahoo.com/markets/stocks/articles/immucell-q1-earnings-rise-y-134500590.html", "source_name": "Market source", "published_at": "2026-05-25T13:45:00", "published_display": "25 May 2026 13:45", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Reaches Settlement Agreement with Norbrook Laboratories", "summary": "ImmuCell Corporation has reached a settlement agreement with Norbrook Laboratories Limited concerning claims related to their 2019 Development Services and Commercial Supply Agreement. Norbrook will pay ImmuCell $2,000,000, and both parties deny admission of liability. TipRanks' ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ICCC-Q/pressreleases/1831969/immucell-reaches-settlement-agreement-with-norbrook-laboratories/", "source_name": "The Globe and Mail", "published_at": "2026-05-19T07:44:27", "published_display": "19 May 2026 07:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Q1 Earnings Call Highlights", "summary": "ImmuCell (NASDAQ:ICCC) reported a record first quarter for 2026, achieving over $10 million in product sales for the first time, a 28.4% increase from the previous year. The company's strategic focus on its First Defense calf scours prevention portfolio and improvements in manufa", "url": "https://www.barchart.com/story/news/1976272/immucell-q1-earnings-call-highlights", "source_name": "Barchart.com", "published_at": "2026-05-16T14:39:40", "published_display": "16 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript", "summary": "ImmuCell Corporation reported a record-setting first quarter in 2026, achieving $10.4 million in revenue, a 28.4% increase year-over-year, and a 34% rise in net income. The company's strategic shift to focus on its \"First Defense\" calf scours preventative product has started yiel", "url": "https://www.insidermonkey.com/blog/immucell-corporation-nasdaqiccc-q1-2026-earnings-call-transcript-1763350/", "source_name": "Insider Monkey", "published_at": "2026-05-16T12:38:45", "published_display": "16 May 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ICCC SEC Filings - Immucell 10-K, 10-Q, 8-K Forms", "summary": "This article provides an overview of Immucell (ICCC) SEC filings, including 10-K, 10-Q, and 8-K forms, which document material events and governance. It highlights recent filings such as the company replacing higher-rate loans with new financing and the initiation of a CEO succes", "url": "https://www.stocktitan.net/sec-filings/ICCC/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-16T06:38:45", "published_display": "16 May 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immucell-corp-iccc-q1-2026-230123813.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T23:01:23+00:00", "published_display": "15 May 2026 23:01", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/65c33d98-9195-32c0-92f6-f866e1f76005/immucell-%28iccc%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-15T14:04:12+00:00", "published_display": "15 May 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immucell-announces-unaudited-financial-results-200500260.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (NASDAQ: ICCC) grows Q1 2026 revenue 28% and boosts earnings", "summary": "ImmuCell Corporation reported strong financial results for Q1 2026, with product sales increasing by 28.4% to $10.36 million and net income rising by 34.2% to $1.94 million. This growth was primarily driven by higher sales volumes and price increases for its First Defense\u00ae produc", "url": "https://www.stocktitan.net/sec-filings/ICCC/10-q-immucell-corp-de-quarterly-earnings-report-9669cf06a55a.html", "source_name": "Stock Titan", "published_at": "2026-05-14T19:40:02", "published_display": "14 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Calf-health maker ImmuCell secures $2M to expand First Defense output", "summary": "ImmuCell (Nasdaq: ICCC) reported a significant increase in Q1 2026 net income to $1.9 million on product sales of $10.4 million, marking a 28.4% year-over-year growth. The company achieved a gross margin of 45.0% and increased its cash position to $6.8 million, bolstered by a $2 ", "url": "https://www.stocktitan.net/news/ICCC/immu-cell-announces-unaudited-financial-results-for-the-quarter-fwwqw8bsbbv6.html", "source_name": "Stock Titan", "published_at": "2026-05-14T19:40:02", "published_display": "14 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Stocks to watch after market on Wednesday: ICCC, COST, STZ (STZ:NYSE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQXzRtOWIyMDVsWkNSWlRab0Y0elpOcWhmbkVESHVpckpIWWpmeTJ4VXRieG4wOUlwN0FONlZISmxJRlg5ZFcycWhUTVJjZFNTaS12R3dqYzFUaUdlM2hWVEZ5WlBIcjlLRzhBZlhrZlVoODBvM29GMG9vQWd3d21aa2dlUDYtR0JseDFwcHNvX1Vzam1KV29INg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQejhXemxoOG9CMFJuQ0pYYUNnT1VnY1IycEFmajNrNUlPREEzNmdGbHhHTklGcTlndFpWRFJ4X1FvX21wcGd2TXRVSWFHVllBbkh3eVJwb19RaF9BdVFnRGV5cXZvUEtkSV9IWWRVZGNNZEswLUNXanpDVV9lQlZuLWZoRzZmU21uWDN6SDlNM3JuN3RUT0htaW5BZHlCNzRla0VZV0lUa3Q?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-26T17:47:29+00:00", "published_display": "26 Dec 2025 17:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation Announces Successful Refinancing of Bank Debt to Enhance Financial Stability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMnFtRVI4WU1GNjJueHdWTDN3Qk9pbldFM3VQcFlISXhXcUdKUFRuOWJ1NnRBUkN3b19JdHdBZE9RRzlNNGltTGJhemthRzdyWmdvREUyZ0EwR2ljZ0pUUXNNVGZiMDRKaklGa1hrNUdDNGx5VFBOU0pnRVEtOEc3TTVObmpNdFZhV3VpQVdsOTViV2h0Y2w3NU5Pa3NkMmdjWXJmdVpXQVp4UV91a09SY181aTRqVGUxbWZzYVJFd3lCWUNvTk55NHNn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "by_tier": {"direct": [{"title": "Price to earnings forward of ImmuCell Corporation \u2013 NASDAQ:ICCC", "summary": "", "url": "https://news.google.com/rss/articles/CBMiogFBVV95cUxOVG0xOUdsSVEzNjhMeUZQb0RMWkdZZjR0NFVEVHVxUHhtSlR3S05oVVhWUGhwVnpVTkhWT3Z2eGY0d1YwOVVsTEt5Z3NkeE5DbjhVeElQanJzbHRrUFltaGNSTWo2Nnhjb3dOc25paEt6V1VscmVVRlN6dFJGcTdLUnFybE5uOU9PRHRzcmlpS0J6a3MtSDFxTlBIVERDQ3JWd2c?oc=5", "source_name": "TradingView", "published_at": "2026-07-15T17:52:14+00:00", "published_display": "15 Jul 2026 17:52", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "How Immucell Corporation (ICCC) Affects Rotational Strategy Timing", "summary": "", "url": "https://news.google.com/rss/articles/CBMi2wFBVV95cUxNUHNpdTV6ei0wQUpXdWpGY1czOU4wTm5oY0JfMXZJM0N3LVlZLXI1X2NJcThEQmM1TVhmZ1g3MUxYRHVtamJEdjVXdE54UDlNM09GSEE0UkhLdkkyVTJtd0tpR3BSSXo1S0FjNURfN2hsbWhNWVlDWUoxVUlpOG1Mci0xRzVLSGs4TDUwbzc0WjVUT0NybmdJeV9fX0xib3g3UkNIaXgyWi02Q2JfSW5KRTBLY0F6Sms0b2R6Zlc4Q3RISXNBSmMtT05zWkZtRDB1Wlp5NVR2UDA4QzQ?oc=5", "source_name": "Stock Traders Daily", "published_at": "2026-07-13T20:54:01+00:00", "published_display": "13 Jul 2026 20:54", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Announces a 12% Increase in Product Sales in Q2 of 2026 and a 21% Increase in the First Six Months of 2026, Based on Preliminary, Unaudited Sales Results", "summary": "ImmuCell Corporation has reported strong preliminary, unaudited sales results for the second quarter and first six months of 2026. The company saw a 11.5% increase in total product sales to $7.2 million in Q2 2026 compared to Q2 2025, primarily driven by a significant 27.7% rise ", "url": "https://www.manilatimes.net/2026/07/10/tmt-newswire/globenewswire/immucell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a-21-increase-in-the-first-six-months-of-2026-based-on-preliminary-unaudited-sales-results/2382009", "source_name": "The Manila Times", "published_at": "2026-07-10T17:09:08", "published_display": "10 Jul 2026 17:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Posts Strong Preliminary Q2 Sales on U.S. Demand", "summary": "", "url": "https://news.google.com/rss/articles/CBMisgFBVV95cUxPRzFQYWtVYUdvakNHRldvVTdIUzhEazVIbE5FakdkdFhHRVJ4eVBuY2piLW9hTVVtbHhsQlhDcUN4X0lPajFWSi1EMUxMSjZwNHRMMXRSZXJtNEF5czVDbHgzLWVpTm53T0hFMElCVVU1S21vUnM4MDhwZ1h1UmNuX3djOEZJSEkxQ2FVTmZPTXRWbWluMmFTTmtvOFVDaS1VdHowTDU0ZUtqUkVNQlEyZjhR?oc=5", "source_name": "TradingView", "published_at": "2026-07-10T13:45:00+00:00", "published_display": "10 Jul 2026 13:45", "sentiment": "positive", "sentiment_pct": 66, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Insider Confidence Rewarded, Stock Hits US$96m Market Cap", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-07-10T10:08:08+00:00", "published_display": "10 Jul 2026 10:08", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell sales jump 12% in Q2 as U.S. demand lifts calf products", "summary": "ImmuCell (Nasdaq: ICCC) announced preliminary, unaudited Q2 2026 product sales of $7.2 million, an 11.5% increase year over year, with domestic sales rising 27.7%. For the first half of 2026, total product sales reached $17.5 million, up 20.9% compared to 2025. Strong U.S. demand", "url": "https://www.stocktitan.net/news/ICCC/immu-cell-announces-a-12-increase-in-product-sales-in-q2-of-2026-and-a2w43qb9wckg.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:09:30", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 80, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell reports Q2 product sales up 11.5% to $7.2M; six\u2011month sales up 20.9% to $17.5M", "summary": "ImmuCell (ICCC) announced preliminary, unaudited product sales for Q2 2026 reached $7.2 million, an 11.5% increase year-over-year, with six-month sales up 20.9% to $17.5 million. The growth was primarily driven by a 27.7% increase in domestic sales, attributed to improved product", "url": "https://www.tradingview.com/news/tradingview:f04eebfa35c19:0-immucell-reports-q2-product-sales-up-11-5-to-7-2m-six-month-sales-up-20-9-to-17-5m/", "source_name": "TradingView", "published_at": "2026-07-09T20:09:30", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 72, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) Q2 2026 sales hit $7.2M as six-month revenue climbs 20.9%", "summary": "ImmuCell Corporation reported preliminary Q2 2026 sales of $7.2 million, an 11.5% increase year-over-year, driven by strong domestic demand, though international sales declined significantly. For the first six months of 2026, total product sales rose 20.9% to $17.5 million. The c", "url": "https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-18ef7c8f2c86.html", "source_name": "Stock Titan", "published_at": "2026-07-09T20:09:30", "published_display": "09 Jul 2026 20:09", "sentiment": "positive", "sentiment_pct": 71, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70 - Inverse ETF Flow", "summary": "", "url": "https://news.google.com/rss/articles/CBMivAFBVV95cUxPUUJpSUtKbExwYldkc1ktaVY2VmxZU3ZoYUotVDg5MlpMZEN1TU11dC1qMjFpVnl3Uzk3aDFMOWZqTjVYZE83MDYyWFQtZ3ZsOF9MNVZIVjJaT0tPaWNsSFlwakl1aHBhbm5KZUxvY0lFeWxBTmg3cXEwTldERVdtM01tTndaZE5jdEVkdUh0bGNhUkNtM1k4ZDRHc3Z2b0NEVXh5akh3eHd3MDBTZUg2RkMtSDhlVjJGWExBZw?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T13:40:14+00:00", "published_display": "01 Jul 2026 13:40", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (ICCC) Gains 1.39% as Stock Approaches Key Resistance at $10.70 - Volume Profile", "summary": "", "url": "https://news.google.com/rss/articles/CBMivgFBVV95cUxNZ2lLNXZKNG5zcmNlcGRtUjdNRl9XbWkyT3pIdHVmVE9ObnF3dHczSlFESUlTbHRMdE8wdm5VbjNxeXoxOHpISGk1VEh4Njd4RE1Dc0lKNWlKRmM0Wjk5UXU0RWg2cDM3Y0d2WTgxQWdnQjFMdkdVOUpSclBJM2xYMWUwTGtrYy1zSGJJdlQ1ckVsMWRuQmswMlJUVENPS1dpR25qTGJ4WDhVNG5GUExtSGx3R2NoX1JaMlI1VWV3?oc=5", "source_name": "dars.gov.et", "published_at": "2026-07-01T13:33:34+00:00", "published_display": "01 Jul 2026 13:33", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell adds Jacee Lancaster to Commercial Team", "summary": "ImmuCell Corp. announced the hiring of Jacee Lancaster as sales and marketing manager for its Western region, marking the company's fifth new hire in three months. Lancaster will focus on supporting dairy and beef producers, veterinarians, and distribution partners in understandi", "url": "https://www.feedstuffs.com/agribusiness-news/immucell-adds-jacee-lancaster-to-commercial-team", "source_name": "Feedstuffs", "published_at": "2026-07-01T14:10:14", "published_display": "01 Jul 2026 14:10", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Zacks Analyst Blog Highlights JPMorgan, Novartis, Qualcomm, Genie and ImmuCell", "summary": "This Zacks Analyst Blog highlights research reports for five companies: JPMorgan Chase & Co. (JPM), Novartis AG (NVS), Qualcomm Inc. (QCOM), Genie Energy Ltd. (GNE), and ImmuCell Corp. (ICCC). The report provides insights into each company's recent performance, growth drivers, an", "url": "https://finance.yahoo.com/markets/stocks/articles/zacks-analyst-blog-highlights-jpmorgan-092600802.html", "source_name": "Market source", "published_at": "2026-06-26T05:26:00", "published_display": "26 Jun 2026 05:26", "sentiment": "positive", "sentiment_pct": 71, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell CEO buys $75,960 in common stock", "summary": "ImmuCell Corp's CEO, Paul Francis Olivier te Boekhorst, recently acquired 8,000 shares of common stock for $75,960. This purchase follows a significant 60.85% jump in the company's shares over the past six months and a strong first quarter in 2026, marking the first time ImmuCell", "url": "https://www.investing.com/news/insider-trading-news/immucell-ceo-buys-75960-in-common-stock-93CH-4752698", "source_name": "Investing.com", "published_at": "2026-06-22T13:10:48", "published_display": "22 Jun 2026 13:10", "sentiment": "positive", "sentiment_pct": 74, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Form 4 ImmuCell Corporation For: 22 June By Investing.com", "summary": "This article reports on a Form 4 filing for ImmuCell Corporation on June 22. Form 4 filings are legally required documents by the U.S. Securities and Exchange Commission (SEC) that must be filed by company insiders when they trade shares of their own company's stock. The article ", "url": "https://ng.investing.com/news/stock-market-news/form-4-immucell-corporation-for-22-june-93CH-2567738", "source_name": "Investing.com Nigeria", "published_at": "2026-06-22T13:10:48", "published_display": "22 Jun 2026 13:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) CEO increases stake with 8,000-share open-market buy", "summary": "ImmuCell CEO Paul Francis Olivier te Boekhorst has increased his direct holdings in the company by purchasing 8,000 shares of common stock at $9.495 per share. This open-market transaction, filed on June 18, 2026, brings his total direct ownership to 17,785 shares. The purchase s", "url": "https://www.stocktitan.net/sec-filings/ICCC/form-4-immucell-corp-de-insider-trading-activity-8199032d5fe4.html", "source_name": "Stock Titan", "published_at": "2026-06-22T12:10:48", "published_display": "22 Jun 2026 12:10", "sentiment": "positive", "sentiment_pct": 73, "event_type": "deals", "event_label": "Deals and strategy", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ICCC's Valuation Remains Premium: Is it Worth Overpaying for?", "summary": "ImmuCell Corporation (ICCC) shares are trading at a premium valuation compared to the industry average, but the article argues that this is justified due to the company's strong operational progress, market-share gains, and long-term growth prospects. Key factors include improved", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ICCC/pressreleases/2540286/icccs-valuation-remains-premium-is-it-worth-overpaying-for/", "source_name": "The Globe and Mail", "published_at": "2026-06-19T09:09:56", "published_display": "19 Jun 2026 09:09", "sentiment": "positive", "sentiment_pct": 75, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Shareholder Structure: Major Shareholders & Institutional Holdings", "summary": "This article provides a detailed breakdown of ImmuCell Corp's (ICCC) shareholder structure, listing major individual and institutional holders. It also presents a historical view of institutional shareholding over several quarters and details recent shareholder activity, includin", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/ownership", "source_name": "TradingKey", "published_at": "2026-06-19T06:09:44", "published_display": "19 Jun 2026 06:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Revenue Breakdown: Business Segments, Regional Revenue & Profit Contribution", "summary": "This article provides a detailed revenue breakdown for ImmuCell Corp (ICCC), highlighting its business segments and regional contributions. The data, updated on April 6, 2026, shows that the First Defense\u00ae product line accounts for the vast majority of revenue at 99.29%, with the", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/revenue", "source_name": "TradingKey", "published_at": "2026-06-19T05:44:27", "published_display": "19 Jun 2026 05:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Dividends & Stock Splits: Historical Payouts and Event Timeline", "summary": "This article provides an overview of ImmuCell Corp's (ICCC) dividend and stock split history. It states that the company has distributed $0.00 in dividends over the past five years and shows no data for past stock splits. The page also displays current stock information for ICCC,", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/dividend-splits", "source_name": "TradingKey", "published_at": "2026-06-19T05:09:44", "published_display": "19 Jun 2026 05:09", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "capital_return", "event_label": "Capital return", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Immucell Shareholders Approve Governance Measures at 2026 Meeting", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5AFBVV95cUxONkFXNml5YjBaUHNJR2hjc2cwc3FFZkcyWjFBZFJIYTFBRnREZjZySkJpZmlBOHh2VFMxR0FncnlNZjMweVlOWFd3ZHVyY1Axd3hqcW4xNElxRGhwWnlNaHBzNmNMV0hsa19iMGUwTlZjSjlwdmVKUmtOMkRyNWljZUduSU1FeUhTZUp1anBhRVBDYkVEX3pBdmlUZjVZQklQNnhuRDhKT2lNTElpdEpKeFpzdVlzS09zT1F0bkUxNWNYVkJBOC1jVXk3NzY2RDZiRXVZbHV3eGhsV0lmbS1kVWZRVHU?oc=5", "source_name": "The Globe and Mail", "published_at": "2026-06-18T07:00:00+00:00", "published_display": "18 Jun 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Valuation: PE, PB & Fair Value Analysis", "summary": "This article provides a valuation analysis for ImmuCell Corp (ICCC), noting its current valuation score of 8.62, which ranks it 76th out of 157 in the Pharmaceuticals industry. The P/E ratio is reported at -153.81, showing a significant deviation from recent highs and lows. Key v", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/company-valuation", "source_name": "TradingKey", "published_at": "2026-06-18T07:44:27", "published_display": "18 Jun 2026 07:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell shareholders approve director elections and key proposals at annual meeting", "summary": "ImmuCell Corporation (NASDAQ:ICCC) shareholders approved the election of seven directors and several key proposals at their 2026 Annual Meeting. Over 81% of eligible shares were represented, and proposals included executive compensation, the 2025 Stock Option and Incentive Plan, ", "url": "https://www.investing.com/news/sec-filings/immucell-shareholders-approve-director-elections-and-key-proposals-at-annual-meeting-93CH-4748058", "source_name": "Investing.com", "published_at": "2026-06-17T19:11:12", "published_display": "17 Jun 2026 19:11", "sentiment": "positive", "sentiment_pct": 73, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (NASDAQ: ICCC) investors approve directors, pay plan, auditor", "summary": "ImmuCell Corporation's stockholders approved all proposals at their 2026 annual meeting, including the election of seven directors", "url": "https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-89a572dcd1e5.html", "source_name": "Stock Titan", "published_at": "2026-06-17T18:19:13", "published_display": "17 Jun 2026 18:19", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Risk Assessment: Volatility, Financial Risk & Investment Risk", "summary": "This article provides a risk assessment for ImmuCell Corp (ICCC), noting its current score of 2.85, ranking 113 out of 157 in the Pharmaceuticals industry. It highlights the company's beta of 0.54, indicating its stock tends to underperform in up-markets but experiences smaller d", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/risk-assesment", "source_name": "TradingKey", "published_at": "2026-06-16T19:10:13", "published_display": "16 Jun 2026 19:10", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "analyst", "event_label": "Analyst action", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Technical Analysis: Support, Resistance, Indicators & Moving Averages", "summary": "This article provides a technical analysis of ImmuCell Corp (ICCC), covering its price momentum score, support and resistance levels, and various technical indicators and moving averages. The current price momentum score for ICCC is 6.44, and the stock is trading between a resist", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/technical", "source_name": "TradingKey", "published_at": "2026-06-16T19:10:13", "published_display": "16 Jun 2026 19:10", "sentiment": "negative", "sentiment_pct": 38, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Earnings Forecast: Future EPS & Revenue Growth Estimates", "summary": "The article provides an earnings forecast for ImmuCell Corp (ICCC), stating that no earnings forecast score is currently available for the company. It notes that the Pharmaceuticals industry average score is 7.84. The article also mentions that relevant data for financial forecas", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/earnings", "source_name": "TradingKey", "published_at": "2026-06-16T12:40:25", "published_display": "16 Jun 2026 12:40", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Institutional Confidence", "summary": "ImmuCell Corp (ICCC) has an institutional shareholding score of 3.00, placing it 94th in the Pharmaceuticals industry. Institutional investors hold 23.86% of the company's shares, an increase of 17.57% quarter-over-quarter. James Simons is the largest institutional shareholder, h", "url": "https://www.tradingkey.com/markets/stocks/nasdaq-iccc/sentiment", "source_name": "TradingKey", "published_at": "2026-06-16T07:11:12", "published_display": "16 Jun 2026 07:11", "sentiment": "positive", "sentiment_pct": 61, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) Q1 2026 Earnings: Positive EPS Surprise Amid Revenue Gap and Stock Dip - Earnings Beat Streak", "summary": "", "url": "https://news.google.com/rss/articles/CBMixgFBVV95cUxQcHVUMm51dC1UNURjMFNBOWVCbk5PZVBXTTFXZzlxTlRXc1FVdHZZRFdoVFdrZ05vWjdQY1QxcU9paTZBb0ladkdFb2RXR1hRYjdaYUpGYmJJbEdHempCT2kzYndVd2ZFcXJOVGRXVUlhcE1nUExpT0RXUTNvQTVtQVMwa1pLdFVoOHVyYjVMcFVQQTA1RW53M3htcU1xZEp2a2R3Y0FPYmlWczlIV0VISDhSOWdzR2Q3c09PYzFlWDhIRmp5Mnc?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-15T07:00:00+00:00", "published_display": "15 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 82, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 93, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Iccell plans $3.5M First Defense capacity boost | ICCC 8-K Filing", "summary": "ImmuCell Corporation (NASDAQ: ICCC) has announced a significant manufacturing capacity expansion for its flagship First Defense\u00ae product line, shifting resources from its previously planned Re-Tain\u00ae production. The first phase, costing approximately $3.5 million and taking about ", "url": "https://www.stocktitan.net/sec-filings/ICCC/8-k-immucell-corp-de-reports-material-event-22781eac1776.html", "source_name": "Stock Titan", "published_at": "2026-06-10T19:39:00", "published_display": "10 Jun 2026 19:39", "sentiment": "positive", "sentiment_pct": 63, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (ICCC) Edges Higher as Stock Tests Resistance Near $10.19 - Bull Pennant", "summary": "", "url": "https://news.google.com/rss/articles/CBMiuAFBVV95cUxOU215VXh2ek9SRld1Y21KWUM0REEwWVBsWTN4VGo2cXVybmF1eDQ5ZjBZRHNuVVZwMnNBbUIxQjN5S1Q2NC15VUU1SkRWaEVBejBaZlVGUGJnQXItS0VNZG1RbU5vbnR5cFZ0WmVvU1g5dDIzeDU3WnRyTVQ4YlVjWGVKWGluQ2FyZER6dExtdXMwTjhYT2tWTVFRTkdLODY2MkxMeE14aG9yRjNGUTh6YzJrY3kxU05x?oc=5", "source_name": "dars.gov.et", "published_at": "2026-06-08T07:00:00+00:00", "published_display": "08 Jun 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Q1 Earnings Rise Y/Y as Sales Climb on Strong Demand", "summary": "ImmuCell (ICCC) reported strong first-quarter 2026 results with product sales up 28.4% to $10.4 million and net income rising 34% to $1.9 million. The company's performance was driven by robust demand for its First Defense calf-scours prevention products, particularly Tri-Shield,", "url": "https://finance.yahoo.com/markets/stocks/articles/immucell-q1-earnings-rise-y-134500590.html", "source_name": "Market source", "published_at": "2026-05-25T13:45:00", "published_display": "25 May 2026 13:45", "sentiment": "positive", "sentiment_pct": 94, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Reaches Settlement Agreement with Norbrook Laboratories", "summary": "ImmuCell Corporation has reached a settlement agreement with Norbrook Laboratories Limited concerning claims related to their 2019 Development Services and Commercial Supply Agreement. Norbrook will pay ImmuCell $2,000,000, and both parties deny admission of liability. TipRanks' ", "url": "https://www.theglobeandmail.com/investing/markets/stocks/ICCC-Q/pressreleases/1831969/immucell-reaches-settlement-agreement-with-norbrook-laboratories/", "source_name": "The Globe and Mail", "published_at": "2026-05-19T07:44:27", "published_display": "19 May 2026 07:44", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "macro", "event_label": "Macro sensitivity", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Q1 Earnings Call Highlights", "summary": "ImmuCell (NASDAQ:ICCC) reported a record first quarter for 2026, achieving over $10 million in product sales for the first time, a 28.4% increase from the previous year. The company's strategic focus on its First Defense calf scours prevention portfolio and improvements in manufa", "url": "https://www.barchart.com/story/news/1976272/immucell-q1-earnings-call-highlights", "source_name": "Barchart.com", "published_at": "2026-05-16T14:39:40", "published_display": "16 May 2026 14:39", "sentiment": "negative", "sentiment_pct": 40, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation (NASDAQ:ICCC) Q1 2026 Earnings Call Transcript", "summary": "ImmuCell Corporation reported a record-setting first quarter in 2026, achieving $10.4 million in revenue, a 28.4% increase year-over-year, and a 34% rise in net income. The company's strategic shift to focus on its \"First Defense\" calf scours preventative product has started yiel", "url": "https://www.insidermonkey.com/blog/immucell-corporation-nasdaqiccc-q1-2026-earnings-call-transcript-1763350/", "source_name": "Insider Monkey", "published_at": "2026-05-16T12:38:45", "published_display": "16 May 2026 12:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ICCC SEC Filings - Immucell 10-K, 10-Q, 8-K Forms", "summary": "This article provides an overview of Immucell (ICCC) SEC filings, including 10-K, 10-Q, and 8-K forms, which document material events and governance. It highlights recent filings such as the company replacing higher-rate loans with new financing and the initiation of a CEO succes", "url": "https://www.stocktitan.net/sec-filings/ICCC/page-5.html", "source_name": "Stock Titan", "published_at": "2026-05-16T06:38:45", "published_display": "16 May 2026 06:38", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corp (ICCC) Q1 2026 Earnings Call Highlights: Record Revenue and Strategic Growth", "summary": "", "url": "https://finance.yahoo.com/markets/stocks/articles/immucell-corp-iccc-q1-2026-230123813.html", "source_name": "GuruFocus.com", "published_at": "2026-05-15T23:01:23+00:00", "published_display": "15 May 2026 23:01", "sentiment": "positive", "sentiment_pct": 83, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 85, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (ICCC) Q1 2026 Earnings Transcript", "summary": "", "url": "https://finance.yahoo.com/m/65c33d98-9195-32c0-92f6-f866e1f76005/immucell-%28iccc%29-q1-2026.html", "source_name": "Motley Fool", "published_at": "2026-05-15T14:04:12+00:00", "published_display": "15 May 2026 14:04", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Announces Unaudited Financial Results for the Quarter Ended March 31, 2026", "summary": "", "url": "https://finance.yahoo.com/sectors/healthcare/articles/immucell-announces-unaudited-financial-results-200500260.html", "source_name": "GlobeNewswire", "published_at": "2026-05-14T20:05:00+00:00", "published_display": "14 May 2026 20:05", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell (NASDAQ: ICCC) grows Q1 2026 revenue 28% and boosts earnings", "summary": "ImmuCell Corporation reported strong financial results for Q1 2026, with product sales increasing by 28.4% to $10.36 million and net income rising by 34.2% to $1.94 million. This growth was primarily driven by higher sales volumes and price increases for its First Defense\u00ae produc", "url": "https://www.stocktitan.net/sec-filings/ICCC/10-q-immucell-corp-de-quarterly-earnings-report-9669cf06a55a.html", "source_name": "Stock Titan", "published_at": "2026-05-14T19:40:02", "published_display": "14 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 77, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 69, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Calf-health maker ImmuCell secures $2M to expand First Defense output", "summary": "ImmuCell (Nasdaq: ICCC) reported a significant increase in Q1 2026 net income to $1.9 million on product sales of $10.4 million, marking a 28.4% year-over-year growth. The company achieved a gross margin of 45.0% and increased its cash position to $6.8 million, bolstered by a $2 ", "url": "https://www.stocktitan.net/news/ICCC/immu-cell-announces-unaudited-financial-results-for-the-quarter-fwwqw8bsbbv6.html", "source_name": "Stock Titan", "published_at": "2026-05-14T19:40:02", "published_display": "14 May 2026 19:40", "sentiment": "positive", "sentiment_pct": 64, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "Stocks to watch after market on Wednesday: ICCC, COST, STZ (STZ:NYSE)", "summary": "", "url": "https://news.google.com/rss/articles/CBMimAFBVV95cUxQXzRtOWIyMDVsWkNSWlRab0Y0elpOcWhmbkVESHVpckpIWWpmeTJ4VXRieG4wOUlwN0FONlZISmxJRlg5ZFcycWhUTVJjZFNTaS12R3dqYzFUaUdlM2hWVEZ5WlBIcjlLRzhBZlhrZlVoODBvM29GMG9vQWd3d21aa2dlUDYtR0JseDFwcHNvX1Vzam1KV29INg?oc=5", "source_name": "Seeking Alpha", "published_at": "2026-04-08T07:00:00+00:00", "published_display": "08 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "The Christmas Party Is Still Ongoing In These Stocks: Nvidia, Sidus Space, Coupang, Vanda Pharmaceuticals, ImmuCell", "summary": "", "url": "https://news.google.com/rss/articles/CBMiqAFBVV95cUxQejhXemxoOG9CMFJuQ0pYYUNnT1VnY1IycEFmajNrNUlPREEzNmdGbHhHTklGcTlndFpWRFJ4X1FvX21wcGd2TXRVSWFHVllBbkh3eVJwb19RaF9BdVFnRGV5cXZvUEtkSV9IWWRVZGNNZEswLUNXanpDVV9lQlZuLWZoRzZmU21uWDN6SDlNM3JuN3RUT0htaW5BZHlCNzRla0VZV0lUa3Q?oc=5", "source_name": "Stocktwits", "published_at": "2025-12-26T17:47:29+00:00", "published_display": "26 Dec 2025 17:47", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "general", "event_label": "Market update", "event_confidence": 35, "tier": "direct", "tier_label": "Direct company coverage"}, {"title": "ImmuCell Corporation Announces Successful Refinancing of Bank Debt to Enhance Financial Stability", "summary": "", "url": "https://news.google.com/rss/articles/CBMiygFBVV95cUxOMnFtRVI4WU1GNjJueHdWTDN3Qk9pbldFM3VQcFlISXhXcUdKUFRuOWJ1NnRBUkN3b19JdHdBZE9RRzlNNGltTGJhemthRzdyWmdvREUyZ0EwR2ljZ0pUUXNNVGZiMDRKaklGa1hrNUdDNGx5VFBOU0pnRVEtOEc3TTVObmpNdFZhV3VpQVdsOTViV2h0Y2w3NU5Pa3NkMmdjWXJmdVpXQVp4UV91a09SY181aTRqVGUxbWZzYVJFd3lCWUNvTk55NHNn?oc=5", "source_name": "Quiver Quantitative", "published_at": "2025-08-12T07:00:00+00:00", "published_display": "12 Aug 2025 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "liquidity", "event_label": "Balance sheet", "event_confidence": 61, "tier": "direct", "tier_label": "Direct company coverage"}], "industry": [{"title": "Q1 Earnings Highs And Lows: Natera (NASDAQ:NTRA) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMilAFBVV95cUxNYmZ3aHMyMjBuNmlEUGN6NWZBZV85cEFWNndJaVNoNEVYNk84MlNKRXJ0RXpRQl9wN1RsekhxM3loY1RRNDJhTnVremtReHhLQWVHS053VzRBUTduSkdqRGt1YkxMMThqZHoydElPX1Zfd3hEMi15VlRwRGRvZ2JqRDFneVVxN0JCYzQ4QlV5TTBEOWx3?oc=5", "source_name": "Market source", "published_at": "2026-07-16T18:49:22+00:00", "published_display": "16 Jul 2026 18:49", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Unpacking Q1 Earnings: Incyte (NASDAQ:INCY) In The Context Of Other Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMinAFBVV95cUxOZExLRk1BSFNPMnpMdEFEWjNtbWlkZUQ1aHJHZEtMZHJHZWZDZUI0ck1FM2JqWG9ncDRSNGxEWHZLemZualBEY3BVVzdiUmZiVmxqMFdnbEczbEpvTFBscnA3YVVMWmQ3TkFsVjBDZzl6VEZQanh1UkRaS2hiRTNPbGFwajRSV1A1amFKcnFhcFVITHdydjJpblVRTWI?oc=5", "source_name": "Market source", "published_at": "2026-07-13T12:30:39+00:00", "published_display": "13 Jul 2026 12:30", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "There May Be Reason For Hope In Puma Biotechnology's (NASDAQ:PBYI) Disappointing Earnings", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-15T07:00:00+00:00", "published_display": "15 May 2026 07:00", "sentiment": "negative", "sentiment_pct": 34, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology's (NASDAQ:PBYI) Conservative Accounting Might Explain Soft Earnings", "summary": "", "url": "https://news.google.com/rss/articles/CBMirgFBVV95cUxNZXcyN1VKc0J0RTFtSER6TGRSZm8xSWs2c0paem5paDd3V0J1cjF6ajhFb29tRFpUWWpxYUhzZjFkSXhYQ0lBNTVlbTdCRERpSXNjaGpDajFPOVlpRS1qV2xHMTRHS2pjVVBZMWFfNzItWE9FeENtQ2duMUxVQm5kOG41eVlrNUpObXp2VlhfekdhMVh2X0hjN3ZFZThZNUdWakFLUXJ4aFBVN2JyR2c?oc=5", "source_name": "Market source", "published_at": "2026-05-14T07:00:00+00:00", "published_display": "14 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Puma Biotechnology, Inc. (NASDAQ:PBYI) Analysts Are Pretty Bullish On The Stock After Recent Results", "summary": "", "url": "https://news.google.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?oc=5", "source_name": "simplywall.st", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "positive", "sentiment_pct": 66, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Earnings Update: Here's Why Analysts Just Lifted Their Puma Biotechnology, Inc. (NASDAQ:PBYI) Price Target To US$5.00", "summary": "", "url": "https://news.google.com/rss/articles/CBMingFBVV95cUxPSUN3RjZYMEJ2VUdKQjJpRkZaUXRzM2NTa05WWmlmWHJnZDlJeUpTdFM5Wmk0SUhjclU2dldTZFIyRmZZeGJSNGM2SUNiSGJSYjh1VjYyR0hPZ2FJbWdsbHExYlhwMW1HRTZ0NUxwQzU1b2g4MGpwSHdoMkdIOUtqOXBBYk92LVk2cEFZMzVISjB3c04ydVBEYWw2cVVsdw?oc=5", "source_name": "Market source", "published_at": "2026-05-11T07:00:00+00:00", "published_display": "11 May 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Q4 Earnings Highlights: Regeneron (NASDAQ:REGN) Vs The Rest Of The Biotechnology Stocks", "summary": "", "url": "https://news.google.com/rss/articles/CBMirAFBVV95cUxNWW9GYm5uRzlBX2ZiZXA3RkdDXzJhaFd2N1ZwR21jaXhiRkZQSTNHT0hMaUFjSGl6VXZfOURKemF2bWlFS1hKTXBjZUw4amdVQ0I4QlVnNmFkY1VTQ25pUjBiZGNDUE9QdWdOZHAxV1I1ejN6UE9WdGpseUdrMVA5MXBXWXJmWDBkZUdWUkxpOURCdlZlbDlQR3M5cjAzaDFtakFNblRTa3c0Q1J6?oc=5", "source_name": "Market source", "published_at": "2026-04-25T07:00:00+00:00", "published_display": "25 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "Biotechnology Stocks Q3 Results: Benchmarking Natera (NASDAQ:NTRA)", "summary": "", "url": "https://news.google.com/rss/articles/CBMiswFBVV95cUxPZzZDSEhwNlVYQU9kNXBMMU5ia0FTU0RxRlYwb0I1RERNODN4N0VwRFZWMUY4ODh3eWNkTkp0UERreFlSTllocGk4a2ZKcGlJVjQ4d1dXWlNnYTc5UlNMZm4wc2xITjRQVzhRb3Z5LXllQmhvUHNIaXB3LXk1RUw1WnRPam9wcVE1MXFxSmVzVF9MVmRyMWIwdVkxS1N3MUJZUzByLWxrVDlSSUk4QnNsXzJYbw?oc=5", "source_name": "Market source", "published_at": "2026-04-21T07:00:00+00:00", "published_display": "21 Apr 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}, {"title": "A Look Back at Biotechnology Stocks\u2019 Q4 Earnings: Incyte (NASDAQ:INCY) Vs The Rest Of The Pack", "summary": "", "url": "https://news.google.com/rss/articles/CBMi5gFBVV95cUxNWEtsYkktQkxQRHpTMHJOZzJaN09fT3R5aUpjZ0xEQTZXZGlCVUk0alZrVXhIRERNOW9feVJ1X0R4VUI2Q0FjUGIwTWpIRXE2dXpCLW9NdVdoSEE5b0JEM18wN2FQSGdXMDZfOGJ3STJPUmQ2VVBIbUQ5djhTZ01RTmpxLTdKRmdhN0U3RE52N0dEUzh4VFZ5c3dDd0ppZ1VYeGc0Mm5oQlU5TGJlQldpVHpoVjlhdXZ6ek0yaTBuQV9UUjNFT19kWFZ4QVViODkwN2ppOFRQU3lHQ1IxdXhrRkFGS3E0QQ?oc=5", "source_name": "TradingView", "published_at": "2026-03-29T07:00:00+00:00", "published_display": "29 Mar 2026 07:00", "sentiment": "neutral", "sentiment_pct": 50, "event_type": "earnings", "event_label": "Earnings", "event_confidence": 53, "tier": "industry", "tier_label": "Industry context"}], "sector": []}, "total_fetched": 91, "total_relevant": 52, "sentiment_summary": {"positive": 23, "negative": 3, "neutral": 26, "score": 59, "total": 52, "label": "Balanced news tone", "tone": "neutral"}, "classifier": {"primary_event": "earnings", "primary_label": "Earnings", "confidence": 75, "events": [{"event": "earnings", "label": "Earnings", "weight": 11.96, "count": 24}, {"event": "general", "label": "Market update", "weight": 11.35, "count": 20}, {"event": "macro", "label": "Macro sensitivity", "weight": 1.65, "count": 3}, {"event": "analyst", "label": "Analyst action", "weight": 1.1, "count": 2}, {"event": "deals", "label": "Deals and strategy", "weight": 0.55, "count": 1}, {"event": "capital_return", "label": "Capital return", "weight": 0.55, "count": 1}], "positive_events": 23, "negative_events": 3}, "market_context": {"has_market_context": true, "latest_close": 10.89, "latest_week": "2026-07-10", "one_week_move": 5.8, "four_week_move": 12.5, "twelve_week_move": 36.5, "trend_signal": "1", "trend_label": "Trend active", "trend_tone": "positive", "market_dynamics": 1.316059, "market_dynamics_buy_signal": false, "relative_strength": 35.201392, "fair_value_gap": 94.7, "fair_value_label": "Materially above fair value", "fair_value_tone": "negative", "expectation_direction": "undecided", "expectation_probability": 48.208, "reaction_label": "Price confirming higher", "reaction_tone": "positive", "market_sentence": "+5.8% over one week, +12.5% over four weeks, trend active, and materially above fair value."}, "interpretation": {"label": "Price moving ahead of tone", "tone": "positive", "classification": "price_leads_news", "summary": "Price is moving more forcefully than the current news tone suggests.", "confidence": 67, "badges": [], "opportunities": [], "risks": [], "event_label": "Earnings", "sentiment_word": "balanced"}, "charts": {"sources": [{"label": "Market source", "count": 8}, {"label": "Stock Titan", "count": 8}, {"label": "TradingKey", "count": 8}, {"label": "TradingView", "count": 4}, {"label": "dars.gov.et", "count": 4}, {"label": "simplywall.st", "count": 3}, {"label": "The Globe and Mail", "count": 3}, {"label": "Investing.com", "count": 2}], "tiers": [{"label": "Direct company coverage", "count": 43}, {"label": "Industry context", "count": 9}, {"label": "Sector context", "count": 0}], "events": [{"label": "Earnings", "count": 24}, {"label": "Market update", "count": 20}, {"label": "Macro sensitivity", "count": 3}, {"label": "Analyst action", "count": 2}, {"label": "Deals and strategy", "count": 1}, {"label": "Capital return", "count": 1}, {"label": "Balance sheet", "count": 1}]}, "insights": [{"label": "Weighted tone", "value": "59/100", "tone": "neutral", "text": "Balanced news tone"}, {"label": "Market reaction", "value": "Price moving ahead of tone", "tone": "positive", "text": "Price is moving more forcefully than the current news tone suggests."}, {"label": "Primary event", "value": "Earnings", "tone": "neutral", "text": "75/100 classification confidence."}, {"label": "Company focus", "value": "43", "tone": "positive", "text": "directly relevant articles"}, {"label": "Source quality", "value": "1", "tone": "positive", "text": "high-authority source matches"}, {"label": "Trend context", "value": "Trend active", "tone": "positive", "text": "+5.8% over one week, +12.5% over four weeks, trend active, and materially above fair value."}, {"label": "Latest direct headline", "value": "Neutral", "tone": "neutral", "text": "Price to earnings forward of ImmuCell Corporation \u2013 NASDAQ:ICCC"}], "updated_at": "2026-07-18T01:16:43.307196+00:00", "disclaimer": "Educational market research only. Not financial, investment, trading, tax, or legal advice."}